Ahead of its time, a GLP-1 drug almost made it out of India

Fifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes management and weight loss. Unfortunately, due to prohibitive clinical trial costs and a skeptical outlook on the obesity market, Zydus chose to shelve further development.